CVRX_OUT_1 [2025-04-29 04:01:02 -0400] 5313 Bytes | 1490 tokens | Cum: 1490 tkns (18.62% of 8k)
==========================================================================

Listen up, partner—it's 4:01 AM on Tue Apr 29, 2025, and I’m revved up about CVRx (CVRX), climbing from $6.73 to $7.84. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

--- COMPANY PROFILE ---
Company: CVRx (CVRX)
IPO: 2021-06-30 (3 Years Ago)
Market Cap: $157,778,354
Shares Outstanding: 26,040,000
Industry: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange: XNAS
Description: CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.

Here’s a list of headlines for CVRx:

Apr-24-25 04:30PM - CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025
Apr-09-25 08:45AM - CVRx Inc: Overreaction Creates Buying Opportunity
Apr-07-25 04:05PM - CVRx Reports Preliminary First Quarter 2025 Financial Results
Feb-12-25 02:45PM - CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim
Feb-11-25 09:55AM - CVRx (CVRX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Feb-07-25 09:55AM - Wall Street Analysts Predict a 25.76% Upside in CVRx (CVRX): Here's What You Should Know
Feb-05-25 02:14AM - CVRx Inc (CVRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Rising Expenses
Feb-04-25 05:45PM - CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates
Feb-04-25 05:45PM 04:49PM - CVRx: Q4 Earnings Snapshot
Feb-04-25 05:45PM 04:05PM - CVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
Feb-03-25 07:08AM - CVRx Inc (CVRX) Q4 2024 Earnings Report Preview: What To Expect
Jan-21-25 04:30PM - CVRx to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call on February 4, 2025
Jan-16-25 10:00AM - CVRx (CVRX) Expected to Beat Earnings Estimates: Should You Buy?
Jan-13-25 08:00AM - CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2024 Financial Results and Issues Fiscal 2025 Guidance
Dec-23-24 04:30PM - CVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Nov-26-24 08:31AM - Cvrx (CVRX) Declined Due To Turbulence In The Direct Sales Team
Nov-20-24 04:30PM - CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference
Nov-04-24 08:00AM - CVRx Announces Positive Outpatient Payment for Barostim Procedure in 2025
Oct-30-24 03:14AM - CVRx Inc (CVRX) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Rising Expenses
Oct-29-24 05:50PM - CVRx (CVRX) Reports Q3 Loss, Tops Revenue Estimates
Oct-29-24 05:50PM 04:46PM - CVRx: Q3 Earnings Snapshot
Oct-29-24 05:50PM 04:05PM - CVRx Reports Third Quarter 2024 Financial and Operating Results

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-02-12T19:45:00Z - CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim
B2 - 2024-12-23T21:30:00Z - CVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
B3 - 2024-09-23T18:08:13Z - Masimo Surges 8.7%: Is This an Indication of Further Gains?
B4 - 2024-08-27T01:00:00Z - Bragar Eagel & Squire, P.C. Is Investigating Arhaus, Cardlytics, and CVRx and Encourages Investors to Contact the Firm
B5 - 2024-08-13T20:00:00Z - CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
B6 - 2024-06-25T10:50:00Z - CVRx Announces Appointment of Robert Allen John as Chief Revenue Officer

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for CVRx (CVRX).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

CVRX_OUT_3 [2025-04-29 04:01:02 -0400] 889 Bytes | 219 tokens | Cum: 1711 tkns (21.39% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/02/12/3025369/0/en/CVRx-announces-new-real-world-evidence-demonstrating-significant-reductions-in-healthcare-utilization-with-Barostim.htmlCVRx's Barostim device has demonstrated significant reductions in hospital visits and length of stay for heart failure patients, according to new real-world evidence presented at the THT 2025 conference and published in the Journal of Cardiac Failure.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CVRX_OUT_5 [2025-04-29 04:01:03 -0400] 1017 Bytes | 288 tokens | Cum: 2001 tkns (25.01% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-24T21:08:08Z - CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8,...
A2 - 2025-04-24T20:42:12Z - IBEX Limited to Announce Third Quarter 2025 Financial Results on May 8th, 2025...
A3 - 2025-04-24T20:42:16Z - CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8,...
A4 - 2025-04-24T20:30:00Z - CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8,...
A5 - 2025-04-24T20:43:36Z - CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8,...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

CVRX_OUT_7 [2025-04-29 04:01:04 -0400] 1181 Bytes | 340 tokens | Cum: 2343 tkns (29.29% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025 | Taiwan News | Apr. 25, 2025 04:30**Date: 2025-04-24Source: {'uri': 'taiwannews.com.tw', 'dataType': 'news', 'title': 'Taiwan News'}URL: https://taiwannews.com.tw/en/news/6094356MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that it plans to release first quarter 2025 financial and operating results after market close on Thursday, May 8, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day.

A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1-800-445-7795 for U.S. callers, or 1

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CVRX_OUT_9 [2025-04-29 04:01:05 -0400] 1183 Bytes | 261 tokens | Cum: 2606 tkns (32.57% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): -785-424-1699 for international callers, approximately ten minutes prior to the start time. Please reference the following conference ID to access the call: CVRXQ125.

About CVRx, Inc.

CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CVRX_OUT_11 [2025-04-29 04:01:06 -0400] 601 Bytes | 165 tokens | Cum: 2773 tkns (34.66% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:

Mark Klausner or Mike Vallie

ICR Westwicke

443-213-0501

[email protected]

Media Contact:

Emily Meyers

CVRx, Inc.

763-416-2853

[email protected]

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CVRX_OUT_13 [2025-04-29 04:01:07 -0400] 1093 Bytes | 286 tokens | Cum: 3061 tkns (38.26% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-07 8-K Item 2.02. Results of Oper and Fin Cond.

On April 7, 2025, CVRx, Inc. (the Company) issued a press release announcing certain preliminary financial results for the first quarter ended March 31, 2025 . A copy of the press release is attached as Exhibit 99.1 and ...

S7 - 2025-02-18 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

Overview

We are a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative and minimally invasive neuromodulation solutions for pa...

S9 - 2025-02-04 8-K Item 2.02. Results of Oper and Fin Cond.

On February 4, 2025, CVRx, Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2024. A copy of the press release is attached as Exhibit 99.1 and is incorporated...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CVRX_OUT_15 [2025-04-29 04:01:07 -0400] 1165 Bytes | 278 tokens | Cum: 3341 tkns (41.76% of 8k)
==========================================================================

Showing S1 (chunk 1 of 1): S1:
Item 2.02. Results of Operations and Financial Condition.

On April 7, 2025, CVRx, Inc. (the Company) issued a press release announcing certain preliminary financial results for the first quarter ended March 31, 2025 . A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.

The information contained in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be filed with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing....

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CVRX_OUT_17 [2025-04-29 04:01:15 -0400] 6844 Bytes | 1933 tokens | Cum: 5276 tkns (65.95% of 8k)
==========================================================================

This is our set of metrics for CVRx.
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+-----------------------+
| Volume: 652,853 | Perf Month: -39.01% | Option/Short: Yes / Yes | Sales Y/Y TTM: 30.53% |
+---------------------+-----------------------+-------------------------+-----------------------+
| Avg Volume: 335.93K | Perf Quarter: -54.62% | Short Float: 7.79% | ROE: -81.58% |
+---------------------+-----------------------+-------------------------+-----------------------+
| Rel Volume: 1.99 | Index: RUT | Short Ratio: 3.64 | ROI: -49.47% |
+---------------------+-----------------------+-------------------------+-----------------------+
| RSI (14): 41.04 | Market Cap: 195.95M | Short Interest: 1.22M | Sales Surprise: 1.81% |
+---------------------+-----------------------+-------------------------+-----------------------+
| ATR (14): 0.81 | Shs Outstand: 25.32M | Beta: 1.37 | EPS Surprise: -14.70% |
+---------------------+-----------------------+-------------------------+-----------------------+
| SMA20: -8.08% | Shs Float: 15.69M | Sales Q/Q: 35.71% | P/E: - |
+---------------------+-----------------------+-------------------------+-----------------------+
| SMA50: -30.71% | Inst Own: 35.07% | Sales past 5Y: 57.98% | Earnings: May 08 AMC |
+---------------------+-----------------------+-------------------------+-----------------------+
| SMA200: -34.37% | Insider Own: 39.75% | Employees: 206 | |
+---------------------+-----------------------+-------------------------+-----------------------+
| Perf Week: 24.09% | Insider Trans: -0.01% | Debt/Eq: 0.71 | |
+---------------------+-----------------------+-------------------------+-----------------------+

The next section covers any insider trading by CVRx officers or majority shareholders (if available).

Inside Trans: CVRx, Inc. (CVRX) by VERRASTRO PAUL (CHIEF MKTG & STRAT OFFICER) on 2025-02-28
- Common Stock: 16000 shares at $0 (D)
- Stock Option (right to buy): 24000 shares at $0 (D)

Inside Trans: CVRx, Inc. (CVRX) by Adamson Philip B. (Chief Medical Officer) on 2025-02-28
- Common Stock: 20000 shares at $0 (D)
- Stock Option (right to buy): 30000 shares at $0 (D)

Inside Trans: CVRx, Inc. (CVRX) by OASHEIM JARED (CHIEF FINANCIAL OFFICER) on 2025-02-28
- Common Stock: 22000 shares at $0 (D)
- Stock Option (right to buy): 33000 shares at $0 (D)

Inside Trans: CVRx, Inc. (CVRX) by John Robert Allen (Chief Revenue Officer) on 2025-02-28
- Common Stock: 55000 shares at $0 (D)
- Stock Option (right to buy): 38000 shares at $0 (D)

Inside Trans: CVRx, Inc. (CVRX) by Hykes Kevin (PRES & CEO) on 2025-02-28
- Common Stock: 98000 shares at $0 (D)
- Stock Option (right to buy): 148000 shares at $0 (D)

No transactions recorded.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 51292000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -59965000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 7.52
Average Volume: 573522.2
30-Day High: 12.98
30-Day Low: 6.03

[Detailed Financials: TTM 2024]
- Total Assets: $133,414,000.00
- Total Liabilities: $62,359,000.00
- Total Equity: $71,055,000.00
- Current Assets: $129,813,000.00
- Current Liabilities: $10,762,000.00

[Income Statement: TTM 2024]
- Revenue: $51,292,000.00
- Net Income: $-59,965,000.00
- Gross Profit: $42,958,000.00
- Operating Income: $-59,490,000.00
- Earnings Per Share (EPS): -2.65

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $15,364,000.00

[Detailed Financials: FY 2024]
- Total Assets: $133,414,000.00
- Total Liabilities: $62,359,000.00
- Total Equity: $71,055,000.00
- Current Assets: $129,813,000.00
- Current Liabilities: $10,762,000.00

[Income Statement: FY 2024]
- Revenue: $51,292,000.00
- Net Income: $-59,965,000.00
- Gross Profit: $42,958,000.00
- Operating Income: $-59,490,000.00
- Earnings Per Share (EPS): -2.65

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $15,364,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of CVRx (CVRX).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about CVRx.

2) MARKET_SCORE[]
This conversation was initiated because CVRX is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for CVRX.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, CVRX could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect CVRX to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of CVRx.

11) ETHICAL_RATING[]
Rate CVRx’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of CVRx.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

CVRX_IN_19 [2025-04-29 04:01:16 -0400] 126 Bytes | 29 tokens | Cum: 5513 tkns (68.91% of 8k)
==========================================================================

====================================
[2025-04-29 04:01:16] # Analysis Completed
Elapsed Time: 15.48 seconds